METHODS OF TREATING PAIN ASSOCIATED WITH OSTEOARTHRITIS OF A JOINT WITH A TOPICAL FORMULATION OF A SPIRO-OXINDOLE COMPOUND
Methods of treating pain associated with osteoarthritis of a joint in a mammal with a pharmaceutical composition comprising a spiro-oxindole compound of the formula: are disclosed. The methods provide excellent penetration of the spiro-oxindole compound into the synovial membrane of the affected joint to effectively reduce the severity of the pain and/or to alleviate the pain with minimal or negligible systemic exposure.
1 . A method of treating pain associated with osteoarthritis of a joint in a mammal, wherein the method comprises administering to the affected joint of the mammal a topical pharmaceutical composition comprising one or more excipients and a therapeutically effective amount of a spiro-oxindole compound having the following formula:
2 . The method of claim 1 wherein the administration is periodic administration.
3 . The method of claim 1 which results in minimal or negligible systemic exposure of the spiro-oxindole compound.
4 . The method of claim 1 which results in a greater concentration of the spiro-oxindole compound in the synovial membrane and synovial fluid of the affected joint than the concentration of the spiro-oxindole compound in the plasma of the mammal.
5 . The method of claim 1 wherein the osteoarthritis is primary osteoarthritis.
6 . The method of claim 1 wherein the osteoarthritis is secondary osteoarthritis.
7 . The method of claim 1 , wherein the topical pharmaceutical composition comprises 2% to 8% (w/w) of the spiro-oxindole compound.
8 . The method of claim 1 wherein the topical pharmaceutical composition comprises 45% to 55% (w/w) PEG 400; 5% to 15% (w/w) Transcutol® P; 2.5% to 7.5% (w/w) oleyl alcohol; 2.5% to 7.5% (w/w) isopropyl myristate; 0.1% w/w to 7.5% (w/w) stearyl alcohol; 0.05% to 1% (w/w) butylated hydroxytoluene; and 15% to 30% (w/w) PEG 3350.
9 . The method of claim 1 , wherein the topical pharmaceutical composition comprises 2.0% (w/w) of the spiro-oxindole compound; 52.9% (w/w) PEG 400; 10% (w/w) Transcutol® P; 5% (w/w) oleyl alcohol; 5% (w/w) isopropyl myristate; 5% (w/w) stearyl alcohol; 0.1% (w/w) butylated hydroxytoluene; and 20% (w/w) PEG 3350.
10 . The method of claim 1 , wherein the topical pharmaceutical composition comprises 4.0% (w/w) of the spiro-oxindole compound; 50.9% (w/w) PEG 400; 10% (w/w) Transcutol® P; 5% (w/w) oleyl alcohol; 5% (w/w) isopropyl myristate; 5% (w/w) stearyl alcohol; 0.1% (w/w) butylated hydroxytoluene; and 20% (w/w) PEG 3350.
11 . The method of claim 1 , wherein the topical pharmaceutical composition comprises 8.0% (w/w) of the spiro-oxindole compound; 46.9% (w/w) PEG 400; 10% (w/w) Transcutol® P; 5% (w/w) oleyl alcohol; 5% (w/w) isopropyl myristate; 5% (w/w) stearyl alcohol; 0.1% (w/w) butylated hydroxytoluene; and 20% (w/w) PEG 3350.
12 . The method of claim 2 wherein the periodic administration is once a day, twice a day, three times a day or four times a day.
13 . The method of claim 2 wherein the periodic administration is once a day.
14 . The method of claim 2 wherein the periodic administration is twice a day.
15 . The method of claim 1 wherein the topical pharmaceutical composition is administered to the skin over and surrounding the affected joint in a dose volume of from about 1.0 μL/cm 2 to about 9.0 μL/cm 2 .
16 . The method of claim 15 wherein the dose volume is from about 1.0 μL/cm 2 to about 4.0 μL/cm 2 of skin.
17 . The method of claim 16 wherein the dose volume is 3.0 μL/cm 2 .
18 . The method of claim 2 wherein the therapeutically effective amount of the topical pharmaceutical composition is from about 500 mg to about 2000 mg per each periodic administration to the affected joint.
19 . The method of claim 18 wherein the therapeutically effective amount of the topical pharmaceutical composition is about 1200 mg per each periodic administration to the affected joint.
20 . The method of claim 1 wherein the therapeutically effective amount of the topical pharmaceutical composition is effective in reducing the severity of the pain or alleviating the pain.
21 . The method of claim 1 wherein the affected joint is a knee.
22 . The method of claim 1 wherein the affected joint is a joint in a hand.
23 . The method of claim 1 wherein the affected joint is an ankle.
24 . The method of claim 1 wherein the affected joint is a joint in the shoulder.
25 . The method of claim 1 wherein the affected joint is a hip.
26 . The method of claim 2 wherein the mammal is human.
27 . The method of claim 26 wherein the periodic administration of the topical pharmaceutical composition is effective in reducing an average evening pain intensity or severity in the affected joint in the human when walking on a flat surface when compared to baseline pain intensity.
28 . The method of claim 26 wherein the periodic administration of the topical pharmaceutical composition is effective in reducing an average daily pain intensity or severity in the affected joint in the human when walking on a flat surface when compared to baseline pain intensity.
29 . The method of claim 26 wherein the periodic administration of the topical pharmaceutical composition is effective in reducing an average morning pain intensity or severity in the affected joint in the human when walking on a flat surface when compared to baseline pain intensity.
30 . The method of claim 26 wherein the periodic administration of the topical pharmaceutical composition is effective in increasing physical function of the affected joint during a daily activity when compared to baseline physical function.
31 . The method of claim 26 wherein the periodic administration of the topical pharmaceutical composition is effective in reducing stiffness of the affected joint when compared to baseline stiffness.
32 . The method of claim 26 wherein the periodic administration of the topical pharmaceutical composition is effective in reducing the intensity or severity of the pain in the affected joint as assessed by a WOMAC, PQAS-R or OMERACT-OARSI questionnaire.
33 . The method of claim 32 wherein the periodic administration of the topical composition is effective in reducing the intensity or severity of the pain by 30% when compared to the baseline intensity or severity of the pain.
34 . The method of claim 32 wherein the periodic administration of the topical composition is effective in reducing the intensity or severity of the pain by 50% when compared to the baseline intensity or severity of the pain.
35 . A method of locally treating pain associated with osteoarthritis of a joint in a mammal with a minimal or negligible systemic exposure, wherein the method comprises increasing the concentration of a spiro-oxindole compound having the following formula:
to a therapeutically effective amount in the synovial membrane of the affected joint in the mammal by administering to the affected joint a topical pharmaceutical composition comprising one or more excipients and a therapeutically effective amount of the spiro-oxindole compound.
36 . The method of claim 35 where the administration is periodic administration.
37 . The method of claim 36 wherein the joint is a knee, a joint in a hand, an ankle, a joint in the shoulder or a hip.
38 . The method of claim 35 wherein the mammal is a human.
39 . A method of treating pain associated with osteoarthritis of a joint in a mammal, wherein the method comprises administering to the affected joint of the mammal a topical pharmaceutical composition comprising one or more excipients and a therapeutically effective amount of a spiro-oxindole compound having the following formula:
and a therapeutically effective amount of one or more other therapeutic agents.
40 . The method of claim 39 where the administration is periodic administration.
41 . The method of claim 39 wherein the one or more other therapeutic agent is acetaminophen.